Haemonetics begins direct sales of OrthoPat product in U.S.

MichaelBaron

NEW YORK (MarketWatch) -- Shares of Haemonetics Corp.
HAE, -2.79%
rose 1.6% to $48.38 on Tuesday after the company said it's making its first direct sales of the OrthoPat surgical blood salvage system in the U.S. following the end of its distribution agreement with Zimmer Orthopedic in August. The company also reaffirmed its outlook for fiscal 2006 for earnings of $1.73 to $1.86 a share. "Customer response to our sales force has been positive, and we are excited about the opportunities that direct sales gives us to sell our entire autotransfusion value proposition," Brian Concannon, a president with the company's patient division. "We expect that the number of customers ordering direct will increase rapidly over the next several months."

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information.
All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.
Intraday data delayed at least 15 minutes or per exchange requirements.